期刊文献+

二次检索

题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

年份

共找到257篇文章
< 1 2 13 >
每页显示 20 50 100
Efficacy of activating blood and resolving stasis therapy for IgA nephropathy:a systematic review and meta-analysis
1
作者 Qiu-Mei Lan Jie Li +4 位作者 Han-Qing Zang Zi-Jun Zhou Ya-Xuan Fang Yun-Ze Xing Bo Yang 《Medical Data Mining》 2024年第2期9-16,共8页
Background:To systematically evaluate the efficacy and safety of activating blood and resolving stasis in patients with IgA nephropathy.Methods:From inception to May 2022,databases including PubMed,Embase,the Cochrane... Background:To systematically evaluate the efficacy and safety of activating blood and resolving stasis in patients with IgA nephropathy.Methods:From inception to May 2022,databases including PubMed,Embase,the Cochrane Library,Web of Science,WanFang database,Chinese Biomedical Database,VIP,and China National Knowledge Infrastructure were searched for randomized controlled trials about enhancing blood circulation and removing stasis for IgA nephropathy.For the articles that satisfied the requirements,quality assessment and meta-analysis were done.Results:Seventeen randomized controlled trials with a total of 1653 patients were included.Meta-analysis showed that activating blood and resolving stasis could increase therapeutic effectiveness(risk ratio(RR)=-0.47,95%confidence interval(CI)(-0.37,-0.2),P=0.0006)and decrease levels of serum creatinine(RR=-0.47,95%CI(-0.37,-0.2),P=0.0006),urea nitrogen(RR=0.85,95%CI(1.44,0.26),P=0.005),24-hour urinary protein quantification(RR=1.6,95%CI(2.44,0.95).P=0.00001),and urine red blood cell count(RR=1.7,95%CI(2.57,0.82),P=0.0001).There was no significant difference between the two groups in terms of security(RR=0.6,95%CI(0.36,1.01),P=0.05).Conclusion:Western medicine combined activating blood and resolving stasis is more efficient than Western medicine therapy alone in treating IgA nephropathy,but it still needs to be supported by additional large-scale,multi-center randomized controlled clinical trials due to the poor quality of the included trials. 展开更多
关键词 IgA nephropathy activating blood and resolving stasis META-ANALYSIS randomized controlled trial blood stasi
下载PDF
瘀滞型肩关节周围炎中医优化方案筛选研究
2
作者 韩继成 张云松 +4 位作者 刘茜 邓伟 高宏伟 孙宁 郭珈宜 《吉林中医药》 2024年第1期68-72,共5页
目的基于随机对照试验进行中医临床治疗优化方案的筛选研究,明确中医治疗瘀滞型肩关节周围炎的最佳临床方案。方法选取2020年6月-2021年12月在长春中医药大学附属医院门诊就诊的瘀滞型肩关节周围炎患者99例,随机分为A、B、C组,3组常规... 目的基于随机对照试验进行中医临床治疗优化方案的筛选研究,明确中医治疗瘀滞型肩关节周围炎的最佳临床方案。方法选取2020年6月-2021年12月在长春中医药大学附属医院门诊就诊的瘀滞型肩关节周围炎患者99例,随机分为A、B、C组,3组常规进行推拿及功能锻炼治疗,在此基础上A组联合药物疗法,B组联合针灸疗法,C组联合药物疗法及针灸疗法,疗程2周,于治疗后1周、2周及3个月对患者进行随访。以视觉模拟标尺评分(visual analogue scale,VAS评分)、Constant-Murley肩关节评分量表、肩关节活动范围、红细胞沉降率(erythrocyte sedimentation rate,ESR)及生化指标评价疗效和安全性。结果共92例患者完成研究。相较于本组治疗前,3组在治疗后1周、2周及3个月VAS评分、Constant-Murley肩关节评分、肩关节活动范围有显著改善(P<0.05),完成治疗后ESR有显著改善(P<0.05),肝肾生化指标无统计学意义(P>0.05)。3组组间比较,治疗后1周疗效无统计学意义(P>0.05),C组2周后及3个月效果明显优于A、B组(P<0.05)。完成治疗后的ESR及肝肾生化指标水平无统计学意义(P>0.05)。3组均未发现严重不良事件,不良反应发生率3组比较,差异无统计学意义(P>0.05)。结论针刺、中药内服及外用等疗法对于瘀滞型肩关节周围炎患者的疼痛和活动受限具有显著疗效,能明显地提高患者的生活质量,综合应用中医治疗手段2周后的中远期疗效明显优于单一手段。 展开更多
关键词 瘀滞型肩关节周围炎 针灸 随机对照试验 优化方案筛选研究
下载PDF
少腹逐瘀汤治疗寒凝血瘀型原发性痛经有效性和安全性的meta分析
3
作者 张梅 黄鹂 +2 位作者 宋梦瑶 潘娜 田怿淼 《河南医学研究》 CAS 2024年第19期3461-3465,共5页
目的对少腹逐瘀汤治疗寒凝血瘀型原发性痛经(PD)的有效性和安全性进行系统评价。方法检索中文和外文数据库关于少腹逐瘀汤治疗寒凝血瘀型PD的随机对照试验。数据提取和质量评估分别由2名独立评估员进行,有效数据则使用RevMan 5.3.3软件... 目的对少腹逐瘀汤治疗寒凝血瘀型原发性痛经(PD)的有效性和安全性进行系统评价。方法检索中文和外文数据库关于少腹逐瘀汤治疗寒凝血瘀型PD的随机对照试验。数据提取和质量评估分别由2名独立评估员进行,有效数据则使用RevMan 5.3.3软件进行meta分析。结果共纳入8个临床对照试验研究,收集病例797例,meta分析研究结果表明,对寒凝血瘀型PD患者,使用少腹逐瘀汤治疗痛经在总有效率、中医症候评分、疼痛视觉模拟评分、前列腺素E_(2)(PGE_(2))方面相较于单纯常规治疗差异有统计学意义(P<0.05)。结论寒凝血瘀型PD患者服用少腹逐瘀汤有较好的疗效,安全性较高,但仍存在一定的局限性,需要更多大样本、高质量、多中心、随机、双盲对照试验加以验证,提供更高级别的循证医学证据支持。 展开更多
关键词 少腹逐瘀汤 寒凝血瘀型原发性痛经 随机对照试验 META分析
下载PDF
脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效及转录组学研究 被引量:2
4
作者 王子杨 刘美志 +4 位作者 胡晓贞 周苗 翁嘉灏 赖志昆 孙永宁 《南京中医药大学学报》 CAS CSCD 北大核心 2024年第4期419-428,共10页
目的观察脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效,并通过转录组学方法初步阐明其可能的作用机制。方法将符合纳入标准的140例气虚血瘀型冠心病心绞痛患者依据随机数字法分为治疗组、对照组各70例,治疗期间对照组脱落3例。对照... 目的观察脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效,并通过转录组学方法初步阐明其可能的作用机制。方法将符合纳入标准的140例气虚血瘀型冠心病心绞痛患者依据随机数字法分为治疗组、对照组各70例,治疗期间对照组脱落3例。对照组予冠心病二级预防西医基础治疗,治疗组在对照组治疗基础上加服脉通君安汤,2组疗程均为8周。治疗前后评估2组患者中医证候积分、加拿大心血管学会(Canadian cardiovascular society,CCS)心绞痛分级、西雅图量表(Seattle angina questionnaire,SAQ)评分、焦虑自评量表(Self-rating anxiety scale,SAS)评分、抑郁自评量表(Self-rating depression scale,SDS)评分及不良反应,并基于性别、年龄、病程相匹配原则选取9例患者治疗前后外周血进行转录组学测序。结果治疗后,2组患者中医证候积分均明显下降(P<0.01),治疗组在改善胸痛、胸闷、气短、神倦乏力及总分方面优于对照组(P<0.05,P<0.01);治疗组CCS心绞痛分级总改善率优于对照组(P<0.05);2组治疗前后SAQ、SAS及SDS评分均显著改善(P<0.01),治疗组SAQ评分改善优于对照组(P<0.05,P<0.01)。转录组学结果显示,治疗前后具有显著差异表达的mRNA有862个,包括509个上调,353个下调;GO分析结果显示差异表达的mRNA生物学过程有666条,主要包括病毒基因表达、翻译启动、RNA分解代谢过程等,细胞组分112条,主要包括黏着斑、核糖体亚基、核斑点等;分子功能有94条,主要包括双链RNA结合、钙黏蛋白结合、转录共调节因子活性等;KEGG分析结果显示差异mRNA富集信号通路包括20条,主要包括甘油磷脂代谢通路、单磷酸腺苷激活的蛋白激酶(AMP-activated protein kinase,AMPK)信号通路、核糖体通路等。结论脉通君安汤能够改善气虚血瘀型冠心病心绞痛患者临床症状,其作用机制为多靶点多通路,可能与甘油磷脂代谢通路、AMPK信号通路、核糖体通路的调节相关。 展开更多
关键词 脉通君安汤 冠心病 心绞痛 气虚血瘀证 转录组测序 随机对照试验 补气活血法
下载PDF
基于“脾统血”理论探析易医脐针对血瘀水停型肝硬化腹水患者肝功能及生活质量的影响
5
作者 刘婷婷 权春分 +4 位作者 费景兰 赵婷婷 薛建霞 孙亭亭 梁盼盼 《中西医结合肝病杂志》 CAS 2024年第10期889-892,共4页
目的:基于“脾统血”理论讨论易医脐针对血瘀水停型肝硬化腹水患者肝功能及生活质量的影响。方法:66例血瘀水停型肝硬化患者按随机数字表法分为治疗组和对照组,每组33例。两组患者均采用基础治疗,治疗组加用易医脐针,1次/d,每疗程10 d,... 目的:基于“脾统血”理论讨论易医脐针对血瘀水停型肝硬化腹水患者肝功能及生活质量的影响。方法:66例血瘀水停型肝硬化患者按随机数字表法分为治疗组和对照组,每组33例。两组患者均采用基础治疗,治疗组加用易医脐针,1次/d,每疗程10 d,治疗2个疗程。观察2组患者治疗前后肝功能(ALT、AST、TBil、Alb)、凝血四项(PT、APTT、FIB、TT)、中医证候评分、超声腹水评分、腹围、体质量及生活质量评分的变化。结果:治疗组患者治疗后ALT、TBil、Alb、PT、APTT、FIB、中医证候评分、超声腹水评分、腹围、体质量及生活质量评分改善程度优于对照组(P<0.05),两组患者AST、TT改善差异无统计学意义(P>0.05)。结论:基础治疗联合易医脐针治疗能够更好地改善血瘀水停型肝硬化腹水患者肝脏功能,减少腹水量,缩小腹围,减轻腹胀等不适症状,提高患者生活质量。 展开更多
关键词 脾统血 易医脐针 血瘀水停 肝功能 凝血功能 生活质量
下载PDF
基于温阳化瘀拟方治疗肝衰竭疗效及安全性Meta分析
6
作者 卢昌林 刘美燕 +6 位作者 陈炳东 黄小桃 梅梦如 刘志芳 曹音 毛德文 龙富立 《亚太传统医药》 2024年第6期181-187,共7页
目的:旨在评估采用温阳化瘀拟方治疗肝衰竭患者的临床疗效及安全性。方法:全面检索建库至2023年7月30日的中国知网、万方数据库、维普网、中华医学期刊全文数据库、读秀、预印本平台、中医药科研数据库、PubMed、Web of Science、Clinic... 目的:旨在评估采用温阳化瘀拟方治疗肝衰竭患者的临床疗效及安全性。方法:全面检索建库至2023年7月30日的中国知网、万方数据库、维普网、中华医学期刊全文数据库、读秀、预印本平台、中医药科研数据库、PubMed、Web of Science、Clinic Trial等数据库中采用温阳化瘀拟方治疗肝衰竭的RCTs,而后通过纳排标准筛选符合要求的文献,对纳入文献质量评估后,组织研究者进行相关数据提取,最后运用RevMan 5.4软件对临床有效率、肝功能(丙氨酸氨基转移酶、门冬氨酸氨基转移酶、总胆红素、白蛋白)、凝血功能(凝血酶原时间、凝血酶原活动度)及中医证候评分、MELD评分、病死率进行Meta分析。结果:温阳化瘀拟方组在临床有效率[RR=1.38,95%CI(1.27,1.50),P<0.000 01]、丙氨酸氨基转移酶[MD=-18.06,95%CI(-22.55,-13.58),P<0.000 01]、门冬氨酸氨基转移酶[MD=-17.35,95%CI(-22.87,-11.82),P<0.000 01]、总胆红素[MD=-53.03,95%CI(-71.03,-35.02),P<0.000 01]、凝血酶原时间[MD=-3.81,95%CI(-4.85,-2.77),P<0.000 01]、凝血酶原活动度[MD=8.80,95%CI(5.84,11.77),P<0.000 01]、白蛋白[MD=3.49,95%CI(1.97,5.01),P<0.000 01]、MELD评分[MD=-2.65,95%CI(-3.81,-1.50),P<0.000 01]、中医证候评分[MD=-3.87,95%CI(-5.00,-2.75),P<0.000 01]、病死率[RR=0.51,95%CI(0.34,0.74),P=0.0005]方面均优于对照组,差异具有统计学意义(P<0.05)。结论:温阳化瘀拟方治疗肝衰竭疗效优于单纯西医综合治疗,可以改善患者临床症状及相应指标。 展开更多
关键词 肝衰竭 温阳化瘀 临床疗效 随机对照试验 META分析
下载PDF
大黄■虫丸治疗非酒精性脂肪性肝炎痰瘀互结证的临床疗效与安全性
7
作者 刘晓隽 费小凡 +1 位作者 贺雷 朱林 《世界中医药》 CAS 北大核心 2024年第15期2323-2328,共6页
目的:观察大黄■虫丸治疗非酒精性脂肪性肝炎(NASH)痰瘀互结证的临床疗效与安全性。方法:选取2020年5月11日至2022年1月20日四川大学华西医院收治的NASH患者,均辨证为痰瘀互结证的患者216例作为研究对象,采用区组随机化方法分为对照组... 目的:观察大黄■虫丸治疗非酒精性脂肪性肝炎(NASH)痰瘀互结证的临床疗效与安全性。方法:选取2020年5月11日至2022年1月20日四川大学华西医院收治的NASH患者,均辨证为痰瘀互结证的患者216例作为研究对象,采用区组随机化方法分为对照组和观察组,每组108例,观察组脱失10例,对照组脱失9例。对照组接受健康宣教,根据病情给予降压、降糖、调脂、保肝降酶等标准化基础治疗;观察组在对照组治疗方法基础上,联用大黄■虫丸。治疗前及治疗后(治疗1年)对比2组肝活检缓解率、肝纤维化扫描仪(FibroScan)测定的肝纤维化评级缓解率、中医证候积分、体质量指数及肝功能指标[血清谷丙转氨酶(GPT)、血清总胆红素(TB)、血清谷草转氨酶(GOT)]、血脂指标[总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)]、临床疗效及安全性。结果:观察组患者肝活检缓解率高于对照组(χ^(2)=14.512,P=0.002),肝纤维化评级改善率高于对照组(χ^(2)=15.550,P=0.001)。观察组临床中医证候总有效率高于对照组(χ^(2)=21.438,P<0.05)。治疗后,2组患者体质量指数及肝功能、血脂指标均较治疗前改善(P<0.05);治疗后,2组体质量指数及血脂指标比较差异无统计学意义(P>0.05),观察组肝功能指标(GPT、GOT、TB)低于对照组(P<0.05)。共发生不良事件37例次,均为轻微不良反应,未经处理或对症治疗后缓解,2组不良事件发生率比较差异无统计学意义(P>0.05)。结论:大黄■虫丸可改善NASH痰瘀互结证患者的肝纤维化、中医证候与肝功能,安全性良好。 展开更多
关键词 大黄■虫丸 非酒精性脂肪性肝炎 痰瘀互结证 肝纤维化 瞬时弹性成像技术 随机对照研究 临床疗效 安全性
下载PDF
Moxibustion with different doses for primary dysmenorrhea of cold congelation and blood stasis type:A randomized controlled trial 被引量:10
8
作者 Wen-ying SHI Rong LUO +3 位作者 Xiao-juan LIU Ying-han LIU Zhi-liang CAO Wei ZHANG 《World Journal of Acupuncture-Moxibustion》 CSCD 2021年第4期275-280,共6页
Objective:To explore the clinical effect differences of moxibustion with different doses on primary dysmenorrhea with cold congelation and blood stasis type.Methods:A total of 60 patients of primary dysmenorrhea were ... Objective:To explore the clinical effect differences of moxibustion with different doses on primary dysmenorrhea with cold congelation and blood stasis type.Methods:A total of 60 patients of primary dysmenorrhea were randomized into an intensified dose group and a conventional dose group.All of the patients were treated with moxibustion.In the intensified dose group,the treatment was given three times daily(once every morning,afternoon and at bedtime successively) and during the trial,1 case was dropped out and 29 cases were included in the statistical analysis finally.In the conventional dose group,the treatment was given once daily and 1 case was dropped out during trial and 29 cases were included in the statistical analysis.The score of visual analogue scale(VAS) at the worst painful time point,the score of dysmenorrhea symptoms and recurrence rate were observed and compared before and after treatment in the patients between the two groups.The clinical therapeutic effects were observed in the two groups too.Results:VAS difference value(D-value) and dysmenorrhea symptoms D-valuebefore and after treatment in the intensified dose group were higher than those in the conventional dose group respectively(both P<0.05).The recurrence rate was 14.29% in the intensified dose group,lower than 42.31% in the conventional dose group,with the statistical significance(P<0.05).The total clinical effective rate was 96.55%in the intensified dose group,higher than 89.66% in the conventional dose group,with the statistical significance(P<0.05).Conclusion:Compared with the conventional dose moxibustion,moxibustion with intensified dose achieves satisfactory therapeutic effect on primary dysmenorrhea of cold congelation and blood stasis type.This therapy is low in recurrent rate and convenient in manipulation,thus it deserves to be promoted in clinical application. 展开更多
关键词 Different moxibustion doses Cold congelation and blood stasis Primary dysmenorrhea Randomized controlled trial(RCT)
原文传递
Effect and Safety of Hydroxysafflor Yellow A for Injection in Patients with Acute Ischemic Stroke of Blood Stasis Syndrome: A Phase Ⅱ , Multicenter, Randomized, Double-Blind, Multiple-Dose, Active-Controlled Clinical Trial 被引量:12
9
作者 HU Ming-zhe ZHOU Zi-yi +10 位作者 ZHOU Zhong-yu LU Hui GAO Min LIU Long-min SONG Hai-qing LIN An-ji WU Qing-ming ZHOU Hong-fei LI Lei WANG Xia CAI Ye-feng 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2020年第6期420-427,共8页
Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind... Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind,multiple-dose,active-controlled phaseⅡtrial was conducted at 9 centers in China from July 2013 to September 2015.Patients with moderate or severe AIS and BSS were randomly assigned to low-,medium-,high-dose HSYAI groups(25,50 and 70 mg/d HSYAI by intravenous infusion,respectively),and a control group(Dengzhan Xixin Injection(灯盏细辛注射液,DZXXI)30 mL/d by intravenous infusion),for 14 consecutive days.The primary outcome was the Modified Rankin Scale(mRS)score 1 at days 90 after treatment.The secondary outcomes included the National Institute of Health Stroke Scale(NIHSS)score 1,Barthel Index(BI)score 95,and BSS score reduced 30%from baseline at days 14,30,60,and 90 after treatment.The safety outcomes included any adverse events during 90 days after treatment.Results:Of the 266 patients included in the effectiveness analysis,66,67,65 and 68 cases were in the low-,medium-,and high-dose HSYAI and control groups,respectively.The proportions of patients in the medium-and high-dose HSYAI groups with mRS score 1 at days 90 after treatment were significantly larger than the control group(P<0.05).The incidences of favorable outcomes of NIHSS and BI at days 90 after treatment as well as satisfactory improvement of BSS at days 30 and 60 after treatment in the medium-and high-dose HSYAI groups were all significantly higher than the control group(P<0.05).No significant difference was reported among the 4 groups in any specific adverse events(P>0.05).Conclusions:HSYAI was safe and well-tolerated at all doses for treating AIS patients with BSS.The medium(50 mg/d)or high dose(75 mg/d)might be the optimal dose for a phaseⅢtrial. 展开更多
关键词 hydroxysafflor yellow A acute ischemic stroke randomized controlled trial blood stasis syndrome Chinese medicine
原文传递
Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome:a network Meta-anal 被引量:6
10
作者 WANG Chao WU Qiong +4 位作者 LI Ping WANG Zhigang LOU Xusheng LI Yuanyuan ZHANG Lin 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2023年第4期640-649,共10页
OBJECTIVE:To evaluate the clinical efficacy of Traditional Chinese Medicine prescriptions for resolving phlegm in the treatment of angina pectoris of phlegmstasis coronary heart disease by a network Meta-analysis.METH... OBJECTIVE:To evaluate the clinical efficacy of Traditional Chinese Medicine prescriptions for resolving phlegm in the treatment of angina pectoris of phlegmstasis coronary heart disease by a network Meta-analysis.METHODS:Randomized controlled trials(RCTs)on clinical efficacy of CHD angina pectoris with interaction of phlegm and blood stasis were searched in PubMed,Springer,the Cochrane Library and Chinese-language databases China National Knowledge Infrastructure,China Science and Technology Journal Database,and Wanfang Data from their inception to December 2021.Literature was screened and literature bias risk was assessed by RevMan5.4 software.The overall response rate,the duration of angina attack,the levels of serum lipids such as total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),and high density lipoprotein cholesterol(HDL-C),and expression of hypersensitive C-reactive protein(hs-CRP)were selected as outcome indicators for network Meta-analysis and mapped using Stata15.1 software.RESULTS:Totally,26 RCTs were included,involving 2098 participants.There were 6 TCM formulas with the effects of dispelling phlegm and removing blood stasis.Taking conventional Western Medicine as the common intervention measures,the results showed that the overall response improvement rate from high to low was displayed as modified Xiaoxianxiong decoction(小陷胸汤,MXD),Danlou tablet(丹蒌片,DT),modified Gualou Xiebai Banxia decoction(瓜蒌薤白半夏汤,MGXBD),modified Wendan decoction(温胆汤,MWD),modified Zhishi Xiebai Guizhi decoction(枳实薤白桂枝汤,MZXGD),and modified Erchen decoction(二陈汤,MED).The sequence of angina attack duration improvement from high to low was MZXGD,MGXBD,DT,MWD,MXD.The sequence of TC improvement from high to low was MZXGD,MED,DT,and MGXBD.Sequence of improving TG from high to low was MED,MZXGD,MGXBD,and DT.For LDL-C improvement,the effect from good to poor was MZXGD,MGXBD,DT,and MED.With regard to HDL-C improvement,the effect was ranked as MED,MZXGD,MGXBD,and DT from good to poor.hs-CRP expression from high to low was MZXGD,MXD,MED,MWD,and MGXBD.CONCLUSION:TCM formula with the effects of dispelling phlegm and removing blood stasis combined with conventional Western Medicine has obvious advantages in treating CHD angina pectoris with interaction of phlegm and blood stasis.MZXGD has great potential in increasing the overall response rate,reducing Duration of angina attack improving blood lipids,and reducing inflammatory factors.However,due to the limitations of extant studies,the conclusions of this study need to be confirmed by numerous reasonably-designed RCTs. 展开更多
关键词 coronary disease angina pectoris phlegm and blood stasis interaction blood lipid inflammatory factors MEDICINE traditional Chinese network Meta-analysis randomized controlled trial
原文传递
Efficacy and Safety of Guihuang Formula in Treating Type Ⅲ Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial 被引量:6
11
作者 LIU Sheng-jing DENG Ying-jun +3 位作者 ZENG Yin ZHAO Ming GUO Jun GAO Qing-he 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2022年第10期879-884,共6页
Objective: To observe the efficacy and safety of Guihuang Formula(GHF) in treating patients with type Ⅲ prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. Methods: Sixty-six type Ⅲ prostati... Objective: To observe the efficacy and safety of Guihuang Formula(GHF) in treating patients with type Ⅲ prostatitis and Chinese medicine syndrome of dampness-heat and blood stasis. Methods: Sixty-six type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome were randomly divided into the treatment group(GHF) and the control group(tamsulosin) using a random number table, with 33 cases each group. The treatment group received GHF twice a day, and the control group received tamsulosin 0.2 mg once daily before bedtime. Patients in both groups received treatment for 6 weeks and was followed up for 2 weeks. The outcomes included the National Institute of Health Chronic Prostatitis Symptom Index(NIH-CPSI) score, Chinese Medicine Symptoms Score(CMSS), expressed prostatic secretions(EPS) and adverse events(AEs). Results: After treatment, the NIH-CPSI total score and domain scores of pain discomfort, urination and quality of life decreased significantly from the baseline in both groups(P<0.05). The CMSS score decreased in both groups(P<0.05). The white blood cell(WBC) count decreased and lecithin body count increased in both groups(P<0.05). GHF showed a more obvious advantage in reducing the pain discomfort and quality of life domain scores of NIH-CPSI, reducing the CMSS score, increasing the improvement rate of the WBC and lecithin body counts, compared with the control group(P<0.05). There were no significant differences in decreasing urination domain score of NIH-CPSI between two groups(P>0.05). In addition, no serious AEs were observed. Conclusion: GHF is effective in treating type Ⅲ prostatitis patients with dampness-heat and blood stasis syndrome without serious AEs.(Registration No. ChiCTR1900026966) 展开更多
关键词 typeⅢprostatitis dampness-heat and blood stasis syndrome Guihuang Formula Chinese medicine randomized controlled trial
原文传递
Effectiveness of flesh-moistening paste in psoriasis vulgaris patients with symptom pattern of blood stasis:a randomized and parallel-controlled trial 被引量:5
12
作者 Guo Xinwei Lang Na +12 位作者 Li Guanru Li Ping Qu Jianhua Zhou Dongmei Wang Ping Cang Zhang Deng BingXu Lou Weihai Xu Jingna Lan Haibing Liu Yumin Zhang Weishu Sun Liyun 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2020年第6期1018-1025,共8页
OBJECTIVE:To evaluate the efficacy and safety of flesh-moistening paste for treating psoriasis vulgaris in patients with blood stasis pattern in terms of Traditional Chinese Medicine(TCM).METHODS:Eudipleural rashes on... OBJECTIVE:To evaluate the efficacy and safety of flesh-moistening paste for treating psoriasis vulgaris in patients with blood stasis pattern in terms of Traditional Chinese Medicine(TCM).METHODS:Eudipleural rashes on both the left and right side of the same patients with psoriasis vulgaris,diagnosed via TCM as blood stasis pattern,were selected as the targeted skin lesions.A randomized,double-blind,parallel-controlled,multicenter controlled trial was conducted.The targeted skin lesions were categorized into either the treatment or control group.The treatment group used the flesh-moistening paste;the control group used a placebo.Both the paste and the placebo were topically applied twice daily for eight weeks.The patients were examined biweekly to evaluate the effects.The two groups were compared in terms of the psoriasis area and severity index(PASI)of the targeted skin lesions,which is scored according to erythema,desquamation,infiltration,area,pruritus,and improvement of skin barrier function.Adverse events were recorded during the study period.SPSS 21.0 was used to analyze the data.RESULTS:Fifty-six patients were enrolled between February 2016 and October 2017.Two were complicated by cardio-cerebrovascular disease and were excluded;thus,54 outpatients were finally enrolled in the study.Four dropped out during the study period:three failed to complete their follow-up visits for unknown reasons,and one exited due to an adverse event.The final trial comprised 50 of the 56 originally selected patients,with a 92.6%completion rate.After 8 weeks of treatment,the targeted skin lesion scores differed significantly(P<0.05).The PASI scores of the targeted skin lesions differed significantly beginning at week 6(P<0.05).The treatment group presented better results than those of the control group.Only one patient had an adverse reaction associated with the treatment.Improvements in skin barrier function differed significantly(P<0.05).CONCLUSION:The flesh-moistening paste demonstrated a reliable curative effect and safety for treating psoriasis vulgaris in patients with blood stasis patterns.The topical paste improved the barrier function of the skin lesions. 展开更多
关键词 PSORIASIS blood stasis Prepared fleshmoistening paste Randomized controlled trial
原文传递
Efficacy of Yangyin Yiqi Huoxue Granule (养阴益气活血颗粒) in Treatment of Ischemic Stroke Patients with Qi-Yin Deficiency and Blood Stasis Syndrome: A Randomized, Double-Blind, Multicenter, Phase-2 Clinical Trial 被引量:4
13
作者 WANG Yu YANG Jie-hong +7 位作者 WAN Hai-tong HE Yu XU Bin Al Chang-shan ZHOU Hui-fen YU Li WAN Hao-fang BIE Xiao-dong 《Chinese Journal of Integrative Medicine》 SCIE CAS CSCD 2021年第11期811-818,共8页
Objective To evaluate the efficacy and safety of Yangyin Yiqi Huoxue Granule(养阴益气活血颗粒,YYHG)in the treatment of ischemic stroke(IS)patients with qi-yin deficiency and blood stasis syndrome(QYDBSS),and to explor... Objective To evaluate the efficacy and safety of Yangyin Yiqi Huoxue Granule(养阴益气活血颗粒,YYHG)in the treatment of ischemic stroke(IS)patients with qi-yin deficiency and blood stasis syndrome(QYDBSS),and to explore its effective dosage.Methods The total of 288 patients were randomly assigned to the YYHG high-dose,YYHG low-dose,positive control(administered Xiaoshuantong Granule,XSTG,消栓通颗粒),or placebo control(administered inert granule)groups(72 cases per group)by software-drived competitive block randomization.The trial was conducted for a 28-day period,with a 180-day follow-up period.The primary outcome was the comprehensive curative evaluation,and secondary outcomes were the National Institute of Health Stroke Scale(NIHSS)score,Barthel activities of daily living(ADL)index score,the quality of life index(QLI)score,and the Chinese medicine syndrome(CMS)score.All analyses were done on an intention-to-treat basis.The clinical safety was also assessed.Results The total of 288 participants were recruited between June 1,2008 and September 30,2009,and 287 patients received intervention;the treatment groups were well balanced at baseline.The comprehensive cure rates of YYHG high-dose,low-dose,positive and placebo control groups were 63.38%,31.94%,36.11%and 6.14%,respectively;there was a statistical difference between the two groups(P<0.01),while the high-dose YYHG treatment group was significantly higher than the other 3 groups(P<0.01).The improvement of NIHSS,ADL,QLI and CMS scores of the YYHG high-dose and low-dose groups was significantly better than that of the positive control group and the placebo control group(P<0.05).In terms of improving the classification of the NIHSS scale and the assessment of the ADL scale,the YYHG high-dose group was significantly better than the other three groups(P<0.05),and the YYHG low-dose group was better than the placebo control group(P<0.01).At the same time,except for the QLI score,the high-dose group was better than the low-dose group(P<0.05).In terms of safety,adverse reactions after YYHG treatment were generally mild(3.78%),and no serious adverse reactions have been reported.Conclusion YYHG is safe and effective in the treatment of IS patients with QYDBSS. 展开更多
关键词 stroke qi-yin deficiency and blood stasis syndrome Chinese medicine randomized controlled trial
原文传递
西医联合温通刮痧治疗寒凝血瘀型原发性痛经效果及对血清前列腺素水平影响 被引量:2
14
作者 许春梅 周敏婷 +1 位作者 岑肖丽 肖珊 《中国计划生育学杂志》 2024年第2期276-281,共6页
目的:分析温通刮痧对寒凝血瘀型原发性痛经效果及对血清前列腺素F2ɑ(PGF2α)、前列腺素E2(PGE_(2))水平影响。方法:选取2022年5月-2023年6月本院收治的原发性痛经患者90例为研究对象,按照完全随机设计程序分为3组各30例,分别在经期给... 目的:分析温通刮痧对寒凝血瘀型原发性痛经效果及对血清前列腺素F2ɑ(PGF2α)、前列腺素E2(PGE_(2))水平影响。方法:选取2022年5月-2023年6月本院收治的原发性痛经患者90例为研究对象,按照完全随机设计程序分为3组各30例,分别在经期给予布洛芬缓释胶囊口服(西医组)、月经干净后予以单纯的温通刮痧治疗(中医组)及西医基础上加以温通刮痧治疗(中西医组);比较3组临床疗效、中医证候积分、视觉模拟评分法(VAS)、COX痛经症状评分量表(CMSS)、PGF2α、PGE_(2)以及腹部疼痛持续时间。结果:治疗后,临床总有效率西医组(63.3%)、中医组(83.3%)、中西医组(90.0%)依次升高;3组小腹冷痛、肢体畏寒、腰骶酸痛等中医证候积分较治疗前均下降且中西医组、中医组均低于西医组;3组VAS、CMSS评分下降,且中西医组(3.60±0.77分、17.16±5.08分)低于西医组(4.67±0.83分、26.45±6.17分)和中医组(4.47±0.84分、23.60±5.94分);3组PGF2α水平、PGF2α/PGE_(2)下降,PGE_(2)水平升高,且中西医组、中医组变化幅度大于西医组;3组腹部疼痛持续时间均下降且西医组(2.03±1.01d)、中医组(1.56±0.79d)、中西医组(1.14±0.55d)依次降低(均P<0.05)。结论:西医联合温通刮痧可有效减轻寒凝血瘀型原发性痛经患者的痛经症状,降低血清PGF2α、PGE_(2)水平,提高临床有效率。 展开更多
关键词 原发性痛经 寒凝血瘀型 温通刮痧 布洛芬缓释胶囊 前列腺素F2ɑ 前列腺素E2 临床疗效 痛经症状
下载PDF
消白汤联合308nm准分子光治疗稳定期白癜风气滞血瘀证临床观察 被引量:2
15
作者 李庆娟 王丽 +6 位作者 徐俊涛 王刚 郭雪枫 王莹 孟威威 张贺 禹欢欢 《实用中医药杂志》 2024年第2期206-209,共4页
目的:观察消白汤联合308nm准分子光治疗稳定期白癜风气滞血瘀证的疗效。方法:96例随机分为对照组和观察组各48例,两组均给予308nm准分子光治疗,观察组加用消白汤治疗。结果:治疗后两组证候积分(主症、次症、舌象、总分),VASI评分,促炎因... 目的:观察消白汤联合308nm准分子光治疗稳定期白癜风气滞血瘀证的疗效。方法:96例随机分为对照组和观察组各48例,两组均给予308nm准分子光治疗,观察组加用消白汤治疗。结果:治疗后两组证候积分(主症、次症、舌象、总分),VASI评分,促炎因子(IL-17、IFN-γ、TNF-α)均降低(P<0.05)且观察组低于对照组(P<0.05)。观察组治疗后白斑复色疗效总有效率高于对照组(P<0.05)。结论:消白汤联合308nm准分子光治疗稳定期白癜风气滞血瘀证疗效较好。 展开更多
关键词 白癜风 气滞血瘀证 消白汤 308nm准分子光 对照治疗观察
下载PDF
芪术化积方治疗肝细胞癌癌前病变患者的随机对照研究 被引量:1
16
作者 宁麟 孙建光 《中国全科医学》 北大核心 2024年第3期335-342,347,共9页
背景肝细胞癌(HCC)存在发病率高、死亡率高的特点,在癌前病变阶段进行早期诊断及时干预可有效降低HCC的发生率,对其防治具有显著意义。现代医学对于HCC癌前病变的治疗存在干预时机难以把握、治疗手段单一等问题,中医药防治HCC癌前病变... 背景肝细胞癌(HCC)存在发病率高、死亡率高的特点,在癌前病变阶段进行早期诊断及时干预可有效降低HCC的发生率,对其防治具有显著意义。现代医学对于HCC癌前病变的治疗存在干预时机难以把握、治疗手段单一等问题,中医药防治HCC癌前病变或许是一种简单有效的新途径。目的观察芪术化积方治疗HCC癌前病变(肝郁脾虚、痰瘀互结证)的临床疗效及安全性。方法纳入2019年10月—2020年3月在山东中医药大学附属医院、威海市中医院、泰安市中医院肝病科门诊就医且符合中医证型“肝郁脾虚、痰瘀互结证”的HCC癌前病变初诊患者为研究对象。收集患者的一般资料[性别、年龄、乙型病毒性肝炎(HBV)后肝硬化史、HCC家族史、10年以上饮酒史],患者的中医证候积分、肝功能指标[丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、白蛋白(ALB)、谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)]、肿瘤标志物指标[甲胎蛋白(AFP)、甲胎蛋白异质体(AFP-L3)、异常凝血酶原(DCP)]、影像学指标(病灶类型、病灶性质、病灶长径)、安全性指标、不良反应。采用随机数字表法将符合纳入标准且完成研究的64例患者分为观察组(n=34)和对照组(n=30),对照组予以抗病毒、抗炎保肝等常规治疗;观察组予以常规治疗联合芪术化积方治疗。疗程为48周,停药后随访48周,观察两组患者治疗周期及随访周期中HCC发生率及并发症的发生情况,比较两组患者治疗前后中医证候改善指标(中医证候积分、总有效率)、肝功能指标、肿瘤标志物指标、影像学指标(病灶长径、病灶稳定率、病灶改善率)、安全性指标(安全率)的差异。结果治疗后两组中医证候积分、ALT、AST、TBIL、GGT、ALP、AFP-L3均低于治疗前,ALB水平高于治疗前(P<0.05);观察组患者治疗后的DCP值、病灶长径均低于治疗前(P<0.05)。组间比较结果显示,观察组中医证候积分、AST、ALP水平低于对照组,ALB水平高于对照组(P<0.05)。治疗周期结束后观察组的中医证候总有效率(91.2%)高于对照组(63.3%)(P<0.05);观察组病灶改善率(35.3%)和病灶稳定率(50.0%)与对照组(20.0%,43.3%)比较,差异无统计学意义(P>0.05)。随访周期结束后观察组HCC发生率(8.8%)与对照组(16.7%)比较,差异无统计学意义(P>0.05);并发症发生率(8.8%)低于对照组(30.0%)(P<0.05)。安全性指标方面,观察组2例出现轻度不良反应,对照组3例出现轻度不良反应,两组均未出现安全性指标异常,观察组安全率(94.1%)与对照组(90.0%)比较,差异无统计学意义(P>0.05)。结论芪术化积方治疗HCC癌前病变(肝郁脾虚、痰瘀互结证),在改善中医证候、改善肝功能、缩小病灶结节、降低远期HCC发生率及减少肝硬化并发症等方面有较好的临床疗效及安全性。 展开更多
关键词 肝细胞 肝细胞癌癌前病变 中医药疗法 芪术化积方 肝郁脾虚、痰瘀互结证 随机对照试验 临床观察
下载PDF
丹红通精方治疗慢性前列腺炎气滞血瘀型临床研究
17
作者 王方月 方春燕 《实用中医药杂志》 2024年第4期605-607,共3页
目的:观察丹红通精方治疗慢性前列腺炎气滞血瘀型的效果。方法:153例随机分为对照组76例和观察组77例,对照组予前列通瘀胶囊治疗,观察组予丹红通精方治疗。结果:总临床疗效率观察组高于对照组(P<0.05)。治疗后两组NIH-CPSI量表疼痛... 目的:观察丹红通精方治疗慢性前列腺炎气滞血瘀型的效果。方法:153例随机分为对照组76例和观察组77例,对照组予前列通瘀胶囊治疗,观察组予丹红通精方治疗。结果:总临床疗效率观察组高于对照组(P<0.05)。治疗后两组NIH-CPSI量表疼痛不适、排尿异常评分均下降,且观察组低于对照组(P<0.05)。两组治疗后生活质量评分均提升,观察组高于对照组(P<0.05)。观察组NIH-CPSI总积分低于对照组(P<0.05)。治疗后两组平均尿流率和最大尿流率水平均升高,且观察组高于对照组(P<0.05)。治疗后两组TNF-α、IL-1β水平均下降,且观察组低于对照组(P<0.05)。观察组不良反应发生率低于对照组(P<0.05)。结论:丹红通精方治疗慢性前列腺炎气滞血瘀型可提高临床疗效。 展开更多
关键词 慢性前列腺炎 气滞血瘀型 丹红通精方 对照治疗观察
下载PDF
血府逐瘀汤辅治慢性胆囊炎气滞血瘀证临床观察
18
作者 岳鹏 韩永强 涂莹莹 《实用中医药杂志》 2024年第3期456-457,共2页
目的:观察血府逐瘀汤治疗慢性胆囊炎气滞血瘀证的疗效。方法:93例分为两组,两组均用西医常规治疗,观察组加用血府逐瘀汤治疗。结果:治疗后两组右上腹痛、纳差、上腹饱胀症状评分均降低,且观察组比对照组低(P<0.05)。观察组总有效率... 目的:观察血府逐瘀汤治疗慢性胆囊炎气滞血瘀证的疗效。方法:93例分为两组,两组均用西医常规治疗,观察组加用血府逐瘀汤治疗。结果:治疗后两组右上腹痛、纳差、上腹饱胀症状评分均降低,且观察组比对照组低(P<0.05)。观察组总有效率比对照组高(P<0.05)。两组TC、TBil、TBA指标均下降,且观察组比对照组低(P<0.05)。观察组不良发应率比对照组低(P<0.05)。结论:血府逐瘀汤辅治慢性胆囊炎气滞血瘀证可提高疗效,且安全。 展开更多
关键词 慢性胆囊炎 气滞血瘀证 血府逐瘀汤 对照治疗观察
下载PDF
益气活血化痰开窍法辅治急性缺血性脑卒中痰瘀阻络证临床观察
19
作者 涂佳峰 刘光巧 曾晓杰 《实用中医药杂志》 2024年第7期1305-1307,共3页
目的:观察益气活血化痰开窍法辅治急性缺血性脑卒中痰瘀阻络证的疗效。方法:72例分为两组,对照组用西药治疗,观察组用西药及中药治疗。结果:观察组总有效率高于对照组(P<0.05),治疗后观察组中医证候积分、NIHSS评分低于对照组(P<0... 目的:观察益气活血化痰开窍法辅治急性缺血性脑卒中痰瘀阻络证的疗效。方法:72例分为两组,对照组用西药治疗,观察组用西药及中药治疗。结果:观察组总有效率高于对照组(P<0.05),治疗后观察组中医证候积分、NIHSS评分低于对照组(P<0.05),两组不良反应比较差异无统计学意义(P>0.05)。结论:益气活血化痰开窍法辅治急性缺血性脑卒中痰瘀阻络证可提高疗效,且安全。 展开更多
关键词 急性缺血性脑卒中 痰瘀阻络证 益气活血化痰开窍法 对照治疗观察
下载PDF
血府逐瘀汤辅治冠心病稳定性心绞痛气滞血瘀型临床研究
20
作者 张自阳 《实用中医药杂志》 2024年第9期1747-1749,共3页
目的:观察血府逐瘀汤辅治冠心病稳定性心绞痛(SAP)气滞血瘀型的效果。方法:100例分为两组,两组均用西药治疗,治疗组加用血府逐瘀汤治疗。结果:总有效率治疗组高于对照组(P<0.05)。治疗后两组心绞痛症状积分、心电图结果、硝酸甘油停... 目的:观察血府逐瘀汤辅治冠心病稳定性心绞痛(SAP)气滞血瘀型的效果。方法:100例分为两组,两组均用西药治疗,治疗组加用血府逐瘀汤治疗。结果:总有效率治疗组高于对照组(P<0.05)。治疗后两组心绞痛症状积分、心电图结果、硝酸甘油停减率及血脂水平均改善,心绞痛症状积分、心电图结果、血脂水平治疗组改善更显著(P<0.05)。结论:血府逐瘀汤辅治冠心病稳定性心绞痛气滞血瘀型可提高疗效。 展开更多
关键词 冠心病稳定性心绞痛 血府逐瘀汤 对照治疗观察
下载PDF
上一页 1 2 13 下一页 到第
使用帮助 返回顶部